Efficient Neutralization of SARS-CoV-2 Omicron and Other VOCs by a Broad Spectrum Antibody 8G3
Ma, H.; Tseng, C.-T. K.; Zong, H.; Liao, Y.; Ke, Y.; Tang, H.; Wang, L.; Wang, Z.; He, Y.; Chang, Y.; Wang, S.; Drelich, A.; Hsu, J.; Tat, V.; Yuan, Y.; Wu, M.; Liu, J.; Yue, Y.; Xu, W.; Zhang, X.; Wang, Z.; Yang, L.; Chen, H.; Bian, Y.; Zhang, B.; Yin, H.; Chen, Y.; Zhang, E.; Zhang, X.; Gilly, J.; Sun, T.; Han, L.; Xie, Y.; Jiang, H.; Zhu, J.
Show abstract
Numerous mutations in the spike protein of SARS-CoV-2 B.1.1.529 Omicron variant pose a crisis for antibody-based immunotherapies. The efficacy of emergency use authorized (EUA) antibodies that developed in early SARS-CoV-2 pandemic seems to be in flounder. We tested the Omicron neutralization efficacy of an early B cell antibody repertoire as well as several EUA antibodies in pseudovirus and authentic virus systems. More than half of the antibodies in the repertoire that showed good activity against WA1/2020 previously had completely lost neutralizing activity against Omicron, while antibody 8G3 displayed non-regressive activity. EUA antibodies Etesevimab, Casirivimab, Imdevimab and Bamlanivimab were entirely desensitized by Omicron. Only Sotrovimab targeting the non-ACE2 overlap epitope showed a dramatic decrease activity. Antibody 8G3 efficiently neutralized Omicron in pseudovirus and authentic virus systems. The in vivo results showed that Omicron virus was less virulent than the WA1/2020 strain, but still caused deterioration of health and even death in mice. Treatment with 8G3 quickly cleared virus load of mice. Antibody 8G3 also showed excellent activity against other variants of concern (VOCs), especially more efficient against authentic Delta plus virus. Collectively, our results suggest that neutralizing antibodies with breadth remains broad neutralizing activity in tackling SARS-CoV-2 infection despite the universal evasion from EUA antibodies by Omicron variant.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD 96%
- Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages 94%
- Potential transmission chains of variant B.1.1.7 and co-mutations of SARS-CoV-2 94%
Similar papers in this journal
- ZRC3308 monoclonal antibody cocktail shows protective efficacy in Syrian hamsters against SARS-CoV-2 infection 96%
- Cell culture model system utilizing engineered A549 cells to express high levels of ACE2 and TMPRSS2 for investigating SARS-CoV-2 infection and antivirals 96%
- SARS-CoV-2 cell-to-cell infection is resistant to neutralizing antibodies 96%
Similar papers in this journal
- Antiviral activity of lambda-carrageenan against influenza viruses in mice and severe acute respiratory syndrome coronavirus 2 in vitro 95%
- SARS-CoV-2-induced humoral immunity through B cell epitope analysis and neutralizing activity in COVID-19 infected individuals in Japan 95%
- Replication of Equine arteritis virus is efficiently suppressed by purine and pyrimidine biosynthesis inhibitors 95%
Similar papers in this journal
- An ACE2 decamer viral trap as a durable intervention solution for current and future SARS-CoV 95%
- Replication Kinetics, Pathogenicity and Virus-induced Cellular Responses of Cattle-origin Influenza A(H5N1) Isolates from Texas, United States 94%
- Robust neutralization assay based on SARS-CoV-2 S-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressed BHK21 cells 94%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.